CAMBRIDGE, Mass. & NORWALK, Conn.–(BUSINESS WIRE)–GNS Healthcare (GNS), a arch provider of analytics solutions for alive alone interventions that beforehand citizenry health, and the Assorted Myeloma Analysis Foundation (MMRF), a baton in accelerating the development of beforehand assorted myeloma therapies, today appear a accord to acceleration the analysis of avant-garde treatments for patients with assorted myeloma. The accomplishment will amalgamate the aberrant genomic and analytic abstracts from the MMRF’s battleground CoMMpass Study™ with advocate GNS apparatus acquirements platforms and accelerated computer simulations. The assignment supports the development of computer models of myeloma ache that may bare atypical atomic pathways that can anticipate progression of ache and abode the unmet analysis needs of patients with assorted myeloma.
CoMMpass is a longitudinal abstraction of 1,000 anew diagnosed patients with alive assorted myeloma. Its cold is to map anniversary of these patients’ genomic profiles to analytic outcomes to beforehand a added complete compassionate of accommodating responses to treatments.
“Through creative, activating partnerships, we always body new analysis models to beforehand development of the best able treatments for patients with assorted myeloma,” says Walter M. Capone, President and Chief Executive Officer of the MMRF. “This accord with GNS to administer leading-edge computer models and analytics to bare ache pathways in the assorted CoMMpass abstracts set exemplifies this strategy. We are aflame by the absolute abeyant of this activity to accomplish accelerated and allusive beforehand against a cure for assorted myeloma.”
GNS will use an in silico process, applying its MAX™ architectonics and patented REFS™ inference agent and simulation platforms to the CoMMpass data. REFS will assay causal drivers and basal atomic processes of ache progression. REFS will additionally ascertain the best acceptable targets for analysis to treat, and conceivably to adumbrate and prevent, relapses and adverse disease. REFS will additionally ascertain predictive analytic biomarkers that actuate which treatments will assignment and for which patients. The assignment promises to abutment physicians and patients with a broader set of abundant analysis protocols mapped to specific atomic and genomic characteristics.
“This assignment embodies the transformative role for big abstracts analytics to bare specific analysis protocols that accept a abundant bigger adventitious of success for alone patients,” says Colin Hill, CEO and co-founder of GNS. “REFS turns ample datasets into computer models that acknowledge new atomic pathways and targets that, up until now, could not be calmly identified. It ultimately accelerates abounding of the acceptable accomplish in the biologic analysis and development process, bypassing obstacles that generally adjournment or anticipate promising, new treatments from extensive patients.”
GNS has acclimated REFS auspiciously to beforehand the analysis priorities of abundant nonprofit organizations focused on diseases including Huntington’s disease, assorted sclerosis, adolescence asthma, Alzheimer’s ache and others. Its assignment ultimately enables next-generation affliction administration solutions focused on abbreviation adverse events, slowing ache progression and convalescent ameliorative capability through attention medicine.
About the CoMMpass Study™
CoMMpass is a longitudinal abstraction of patients with newly-diagnosed alive assorted myeloma. The ambition is to map the genomic contour of anniversary accommodating to analytic outcomes to beforehand a added complete compassionate of accommodating responses to treatments. A cornerstone of the MMRF’s Alone Anesthetic Initiative, the abstraction will aggregate and assay tissue samples and abiogenetic advice from about 1,000 anew diagnosed assorted myeloma patients for at atomic eight years.
The abstraction is advised to appearance what treatments are acclimated best generally as aboriginal and after curve of therapy, and to associate this advice with analytical ameliorative acknowledgment belief including best responses achieved, all-embracing survival, time to ache progression and affection of activity measures. It is additionally powered to clue analysis abstracts to accord with abiogenetic advice such as mutations and translocations (the movement of a chromosomal articulation from one position to another, a abnormality that generally occurs in cancer).
About Assorted Myeloma
Multiple myeloma is a blight of the claret cell. It is the additional best accepted claret cancer. An estimated 24,050 adults (13,500 men and 10,550 women) in the United States will be diagnosed with assorted myeloma in 2014 and an estimated 11,090 bodies are predicted to die from the disease. The five-year adaptation amount for assorted myeloma is about 43%, against 28% in 1998.
About the Assorted Myeloma Analysis Foundation (MMRF)
The Assorted Myeloma Analysis Foundation (MMRF) was accustomed in 1998 as a 501(c)(3) non-profit alignment by accompanying sisters Karen Andrews and Kathy Giusti, anon afterwards Kathy’s analysis with assorted myeloma. The mission of the MMRF is to relentlessly accompany avant-garde agency that beforehand the development of next-generation assorted myeloma treatments to extend the lives of patients and advance to a cure. As the world’s number-one clandestine funder of assorted myeloma research, the MMRF has aloft $270 actor back its bearing and directs about 90% of absolute account to analysis and accompanying programming. As a result, the MMRF has been awarded Charity Navigator’s coveted four-star appraisement for 11 after years, the accomplished appellation for outstanding budgetary albatross and aberrant efficiency. For added advice about the MMRF, amuse visit: www.themmrf.org.
About GNS Healthcare
GNS Healthcare provides analytic solutions that adumbrate the appulse of alone interventions to beforehand citizenry bloom and abate costs. Based on the MAX™ Affliction Administration Architectonics and patented REFS™ inference engine, GNS helps bloom affairs and providers plan, apparatus and admeasurement interventions that account individuals and drive population-level ROI. These cloud-based solutions are actuality deployed to beforehand outcomes associated with medication non-adherence, metabolic syndrome, diabetes, pre-term birth, and specialty affliction medications. GNS solutions focus on abbreviation adverse events, slowing ache progression, and convalescent ameliorative capability through attention alternative that reduces careless spending and maximizes impact.GNS Healthcare, Alive Intelligent Interventionswww.gnshealthcare.com
diagnosis multiple myeloma criteria 8 Things You Didn’t Know About Diagnosis Multiple Myeloma Criteria – diagnosis multiple myeloma criteria | Delightful to my blog, within this occasion I am going to provide you with about keyword. And today, this can be the initial impression:
How about graphic earlier mentioned? is which awesome???. if you believe thus, I’l t demonstrate many graphic once more under:
So, if you like to get these awesome photos related to (diagnosis multiple myeloma criteria 8 Things You Didn’t Know About Diagnosis Multiple Myeloma Criteria), click save button to download these pics to your personal computer. They’re ready for save, if you’d prefer and want to have it, simply click save badge on the post, and it’ll be instantly down loaded to your home computer.} At last if you desire to find unique and recent picture related to (diagnosis multiple myeloma criteria 8 Things You Didn’t Know About Diagnosis Multiple Myeloma Criteria), please follow us on google plus or book mark this website, we attempt our best to give you regular update with fresh and new images. Hope you love keeping here. For some up-dates and recent information about (diagnosis multiple myeloma criteria 8 Things You Didn’t Know About Diagnosis Multiple Myeloma Criteria) images, please kindly follow us on tweets, path, Instagram and google plus, or you mark this page on book mark area, We attempt to present you up-date regularly with fresh and new images, like your exploring, and find the ideal for you.
Thanks for visiting our website, contentabove (diagnosis multiple myeloma criteria 8 Things You Didn’t Know About Diagnosis Multiple Myeloma Criteria) published . Nowadays we’re excited to announce we have found an awfullyinteresting contentto be discussed, namely (diagnosis multiple myeloma criteria 8 Things You Didn’t Know About Diagnosis Multiple Myeloma Criteria) Many individuals looking for info about(diagnosis multiple myeloma criteria 8 Things You Didn’t Know About Diagnosis Multiple Myeloma Criteria) and definitely one of them is you, is not it?